Trial of an Inactivated Yellow Fever Virus Vaccine

Status Completed

Clinical Trial Summary

This trial will be a randomized, placebo controlled, double-blind (within dosing group), dose escalation Phase 1 trial, evaluating dosages of 1 mcg and 5 mcg of HydroVax-002 YFV vaccine given intramuscularly on Day 1 and Day 29 in up to 25 healthy adults healthy adults ≥ 18 and < 50 years of age. The primary objective is to assess the safety, reactogenicity, and tolerability of the HydroVax-002 YFV vaccine administered intramuscularly in a two-dose series on Days 1 and 29 at a dose of 1 mcg or a dose of 5 mcg.

Clinical Trial Description

This trial will be a randomized, placebo controlled, double-blind (within dosing group), dose escalation Phase 1 trial evaluating dosages of 1 mcg and 5 mcg of HydroVax-002 YFV vaccine given intramuscularly on Day 1 (the day of first vaccination is defined as Day 1) and Day 29 in healthy adults ≥ 18 and < 50 years of age. The study will consist of two dosing groups of HydroVax-002 YFV vaccine to be enrolled sequentially. Each dose group will consist of 10 individuals who receive HydroVax-002 YFV, as well as 5 total subjects who receive placebo. Each dose-group will include a sentinel subgroup consisting of 3 vaccine and 1 placebo recipient. In each of the two (1 mcg and 5 mcg) dose phases, enrollment is halted after the dose 1 vaccination of the sentinel subgroup. Following assessment of safety and reactogenicity data of Group 1 by the Safety Monitoring Committee (SMC), the vaccine dose will be increased to 5 mcg for Group 2. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT05172544
Study type	Interventional
Source	Najit Technologies, Inc.
Contact
Status	Completed
Phase	Phase 1
Start date	January 13, 2022
Completion date	April 24, 2023

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT01436396` - Study of Yellow Fever Vaccine Administered With Tetravalent Dengue Vaccine in Healthy Toddlers	Phase 3
Recruiting	`NCT05568953` - An Experimental Medicine Decipher of a Minimum Correlate of Cellular Immunity	Phase 2
Recruiting	`NCT05447377` - A Study of SII Yellow Fever Vaccine to Compare Safety and Immunogenicity With STAMARIL® In Healthy Infants	Phase 3
Active, not recruiting	`NCT05011123` - Study on an Investigational Yellow Fever Vaccine Compared With Stamaril in Adults in Europe and Asia	Phase 2
Completed	`NCT04267809` - Modulate Cellular Stress in the Immune Cells to Reduce Rate of Symptomatic Viral Infection	Phase 2
Completed	`NCT01943305` - The Role of Pre-existing Cross-reactive Antibodies in Determining the Efficacy of Vaccination in Humans	Phase 2
Completed	`NCT02991495` - Immunogenicity and Safety of Fractional Doses of Yellow Fever Vaccines (YEFE)	Phase 4
Not yet recruiting	`NCT03725618` - Immunogenicity of Fractional One-fifth and One-half Doses of Yellow Fever Vaccine Compared to Full Dose in Children 9-23 Months Old	Phase 4
Completed	`NCT01466387` - A Phase 3b, Randomized, Open-Label Study to Evaluate the Safety and Immunogenicity of Select Travel Vaccines When Administered Concomitantly With MenACWY in Adults	Phase 3
Completed	`NCT04059471` - Non- Inferiority Fractional-doses Trial for Yellow Fever Vaccine	Phase 4
Completed	`NCT02572518` - Immunity After Two Doses of Yellow Fever Vaccine	N/A
Recruiting	`NCT00694655` - Human Immune Responses to Yellow Fever Vaccination	Phase 4
Not yet recruiting	`NCT05332197` - Booster Vaccine for Yellow Fever	Phase 3
Recruiting	`NCT05421611` - A Study of SII Yellow Fever Vaccine to Compare Safety and Immunogenicity With STAMARIL	Phase 3
Completed	`NCT03116802` - Yellow Fever Vaccine on Statin/ Non Statin Subjects	Phase 2
Completed	`NCT02743455` - A Trial to Evaluate the Safety, Reactogenicity, and Immunogenicity of MVA-BN Yellow Fever Vaccine With and Without Montanide ISA-720 Adjuvant in 18-45 Year Old Healthy Volunteers	Phase 1
Completed	`NCT01426243` - The Yellow Fever Vaccine Immunity in HIV Infected Patients : Development of New Assays for Virological and Immunological Monitoring in HIV Infected Patient.	Phase 3
Completed	`NCT00982137` - Study of Live Attenuated Japanese Encephalitis Vaccine (ChimeriVax™-JE) and Yellow Fever Vaccine (STAMARIL®)	Phase 2
Active, not recruiting	`NCT04269265` - The Effect of Inflammation and Damage to Lymph Node Structures on Durable Protective Immunity Following Yellow Fever Vaccination	Phase 1/Phase 2
Completed	`NCT03870061` - Evaluation of an Infant Immunization Encouragement Program in Nigeria	N/A